|Bid||0.01 x 0|
|Ask||0.02 x 0|
|Day's Range||0.02 - 0.02|
|52 Week Range||0.01 - 0.06|
|Beta (3Y Monthly)||-1.21|
|PE Ratio (TTM)||N/A|
|Earnings Date||Dec 5, 2016 - Dec 9, 2016|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.52|
TSX-V: MFS) ("Medifocus" or the "Company"), a biotechnology company with a portfolio of medical products encompassing thermotherapy systems for the treatment of Benign Prostatic Hyperplasia (BPH) and Breast Cancer, is pleased to announce that the United States Food and Drug Administration (FDA) has completed the review of the company's rigorous FDA mandated Post Approval Study (PAS). The 5-year follow-up study has satisfactorily fulfilled the PAS requirements.
LONDON, UK / ACCESSWIRE / January 11, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: OrganiGram Holdings, Medifocus, ...
COLUMBIA, MD / ACCESSWIRE / January 9, 2018 / Medifocus, Inc. (OTCQB: MDFZF; TSX-V: MFS) ("Medifocus" or the "Company"), a biotechnology company with a portfolio of medical products ...